Description

The widespread use of protease inhibitors (pis) in the treatment of HIV has resulted in the emergence of viral strains with extensive cross-resistance and decline in the effectiveness of the available pis. So there was need for new pis that are safe, easy to use, tolerable, and effective against both resistant and wild-type HIV strains which provide durable suppression in treatment-experienced HIV patients.

Daruvir is the india ‘s first third generation protease inhibitor for treatment experienced patients. It contains 300 mg daruvir.

Indication : daruvir is indicated for the adult treatment-experienced patient.
Dosage : the recommended oral dose of daruvir t ablets is 600 mg (two 300 mg tablets) taken with 100 mg twice daily and with food.Discount Price Call

The unique features of daruvir are:

potent anti-hiv activity against a variety of multidrug-resistance hiv strains inhibits dimerization and proteolytic activity of hiv-1 protease. boosted daruvir has the highest genetic barrier to resistance. possesses better diffusion to sanctuary sites such as the genital tract and cns. enhances the choice of pis for constructing a second line regimen. useful as a component of a third line regimen for triple class experienced patients.